RxDoctor Payments Data

Brian Wong, MD

Pulmonary Disease · Torrance, CANPI 1316926488

Payments from drug & device makers

$388in general payments, 2019–2025

Across 10 payments — averaging $38.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$144
  • Stryker$140
  • Grifols USA, LLC$75
  • Johnson & Johnson$15
  • AstraZeneca$13

What the payments were for

  • Food & beverage$388100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$388 in reported general payments places this provider in the 30th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$224,584
Medicare patients
873
Services billed
2,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate45$578,522
Trelegy ElliptaFluticasone/Umeclidin/Vilanter336$377,495
Breo ElliptaFluticasone/Vilanterol153$99,564
EliquisApixaban48$46,326
Spiriva RespimatTiotropium Bromide47$43,028
Arnuity ElliptaFluticasone Furoate117$41,618
Breztri AerosphereBudesonide/Glycopyr/Formoterol55$40,062
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr43$35,816
Incruse ElliptaUmeclidinium Bromide53$31,705
Advair HfaFluticasone Propion/Salmeterol66$27,326
Wixela InhubFluticasone Propion/Salmeterol110$24,500
Fluticasone-SalmeterolFluticasone Propion/Salmeterol127$23,776
DuleraMometasone/Formoterol51$23,538
Spiriva HandihalerTiotropium Bromide33$21,521
SymbicortBudesonide/Formoterol Fumarate40$18,830

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler$13$65,798110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →